Cytokine involvement in cancer anorexia/cachexia: Role of megestrol acetate and medroxyprogesterone acetate on cytokine downregulation and improvement of clinical symptoms

Critical Reviews in Oncogenesis

Volumn 9, Issue 2, 1998, Pages 99-106

  Mantovani, Giovanni ^a   Macciò, Antonio ^a   Lai, Paola ^a   Massa, Elena ^a   Ghiani, Massimo ^a   Santona, Maria Cristina ^a  

^a NONE

Author keywords

Cancer anorexia cachexia syndrome; Cytokines; Medroxyprogesterone acetate; Megestrol acetate

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYTOKINE; EPIRUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 2; INTERLEUKIN 6; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; RECOMBINANT INTERLEUKIN 2; SEROTONIN; TUMOR NECROSIS FACTOR;

ADVANCED CANCER; ANOREXIA; ARTICLE; BLOOD TOXICITY; CACHEXIA; CYTOKINE PRODUCTION; DRUG MECHANISM; HEAD AND NECK CARCINOMA; HUMAN; INFLAMMATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MONONUCLEAR CELL; MUSCLE MASS; ORAL DRUG ADMINISTRATION; SUBCUTANEOUS DRUG ADMINISTRATION; WEIGHT REDUCTION;

EID: 0032461787     PISSN: 08939675     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevOncog.v9.i2.10     Document Type: Article

References (45)

1. Aisner, J., N. S. Tchekmedyian, N. Tait et al.: Studies of high-dose megestrol acetate: potential applications in cachexia. Semin. Oncol., 15 [2 Suppl 1]:68-75 (1988).
2. Aune, T. M., H. W. Golden, and K. M. McGrath: Inhibitors of serotonin synthesis and antagonists of serotonin 1A receptors inhibit T lymphocyte function in vitro and cell-mediated immunity in vivo. J. Immunol., 153:489-498 (1994).
3. Brennan, M. R.: Uncomplicated starvation vs, cancer cachexia. Cancer Res., 37:2359-2364 (1997).
4. Bruera, E., K. Macmillan, N. Kuhen et al.: A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer. Cancer, 66:1279-1282 (1990).
5. Bruera, E.: Clinical management of anorexia and cachexia in patients with advanced cancer. Oncology, 49[Suppl 2]:35-42 (1992).
6. Busbridge, J., M. J. Dascombe, and S. Hoopkins: Acute central effects of interleukin-6 on body temperature, thermogenesis and food intake in the rat. Proc. Nutr. Soc., 38:48A (1989).
7. Devereaux, D. F., T. G. Redgrave, M. Tilton et al.: Intolerance to administered lipids in tumor bearing animals. Surgery, 100:292-297 (1984).
8. Downer, S., A. Joel, H. Allbright et al.: A double-blind placebo-controlled trial of medroxyprogesterone acetate (MPA) in cancer cachexia. Br. J. Cancer, 67:1102-1105 (1993).
9. Espat, N. J., E. M. Copeland, and L. L. Moldawer: Tumor necrosis factor and cachexia: a current perspective. Surg. Oncol., 3:255-262 (1994).
10. Gebbia, V., A. Testa, and N. Gebbia: Prospective randomized trial of two dose levels of megestrol acetate in the management of anorexia-cachexia syndrome in patients with metastatic cancer. Br. J. Cancer, 73:1576-1580 (1996).
11. Gelin, J., L. L. Moldawer, and C. Lonnroth: Role of endogenous tumor necrosis factor alfa and interleukin 1 for experimental tumor growth and the development of cancer cachexia. Cancer Res., 51:415-421 (1991).
12. Heber, D., L. O. Byerley, and J. Chi: Pathophysiology of malnutrition in the adult cancer patient. Cancer Res., 58:1867-1873 (1986).
13. Loprinzi, C. L., A. M. Bernath, D. J. Schaid et al.: Phase III evaluation of 4 doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. Oncology, 51[Suppl. 1]:2-7 (1994).
14. Loprinzi, C. L., N. M. Ellison, D. J. Schaid et al.: Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J. Natl. Cancer Inst., 82:1127-1132 (1990).
15. Loprinzi, C. L., D. J. Schaid, A. M. Dose et al.: Body-composition changes in patients who gain weight while receiving megestrol acetate. J. Clin. Oncol., 11:152-154 (1993).
16. Mantovani, G., P. Lai, M. Ghiani et al.: Weekly Cisplatin + Epidoxorubicin + Medroxyprogesterone acetate + r-Interleukin-2 in advanced (stage IIIB-IV) lung cancer (NSCLC). Preliminary results of a dose-finding study. Abstracts 8th International Congress on Anti-Cancer Treatment, Paris, February 3rd-6th, 1998, 83.
17. Mantovani, G., A. Macciò, A. Bianchi et al.: Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial. Cancer, 77:941-948 (1996a).
18. Mantovani, G., A. Macciò, A. Bianchi et al.: Megestrol acetate in neoplastic anorexia/cachexia: clinical evaluation and comparison with cytokine levels in patients with head and neck carcinoma treated with neoadjuvant chemotherapy. Int. J. Clin. Lab. Res., 25:135-141 (1995).
19. Mantovani, G., A. Macciò, S. Esu et al.: Evidence that cisplatin induces serotonin release from human peripheral blood mononuclear cells and that methylprednisolone inhibits this effect. Eur. J. Cancer, 32A:1983-1985 (1996).
20. Mantovani, G., A. Macciò, S. Esu et al.: Medroxyprogesterone acetate reduces the in vitro production of cytokines and serotonin involved in anorexia/cachexia and emesis by peripheral blood mononuclear cells of cancer patients. Eur. J. Cancer, 33:602-607 (1997).
21. Mantovani, G., A. Macciò, P. Lai et al.: Medroxyprogesterone acetate and megestrol acetate reduce cisplatin-induced serotonin release from human peripheral blood mononuclear cells of cancer patients. Oncol. Rep., 5:121-124 (1998a).
22. Matthys, P. and A. Billiau: Cytokines and cachexia. Nutrition, 13:763-770 (1997).
23. McLaughlin, C. L., G. J. Rogan, and J. Ton: Food intake and body temperature responses of rat to recombinant interleukin 1 beta and a tripeptide interleukin 1 beta antagonist. Physiol. Behav., 52:1155-1160 (1992).
24. McNamara, M. J., H. R. Alexander, and J. A. Norton: Cytokines and their role in the pathophysiology of cancer cachexia. J. Parent Enter. Nutr., 16[Suppl. 6]:50S-55S (1992).
25. Moldawer, L. L., C. Andersson, and J. Gelin: Regulation of food intake and hepatic protein synthesis by recombinant-derived cytokines. Am. J. Physiol., 254:6450-6456 (1988).
26. Moldawer, L. L. and E. M. Copeland: Proinflammatory cytokines, nutritional support, and the cachexia syndrome: interactions and therapeutic options. Cancer, 79:1828-1839 (1997).
27. Moldawer, L. L., J. Gelin, and T. Schersten: Circulating interleukin 1 and tumor necrosis factor during inflammation. Am. J. Physiol., 253:R922-R928 (1987).
28. Moldawer, L. L., M. A. Rogy, and S. F. Lowry: The role of cytokines in cancer cachexia. J. Parent Enter. Nutr., 16:43S-49S (1992).
29. Nelson, K. and D. Walsh: Management of the anorexia/ cachexia syndrome. Cancer Bull., 43:403-406 (1991).
30. Noguchi, Y., T. Yoshikawa, A. Matsumoto et al.: Are cytokines possible mediators of cancer cachexia? Surg. Today, 26:467-475 (1996).
31. Reitmeier, M. and R. C. Hartenstein: Megestrol acetate and determination of body composition by bioelectrical impedence analysis in cancer cachexia. Proc. Annu. Meet. Am. Soc. Clin. Oncol., 9:A1256 (1990).
32. Schmoll, E., H. Wilke, R. Thole et al.: Megestrol acetate in cancer cachexia. Semin. Oncol., 18[Suppl. 2]:32-34 (1991).
33. Sherry, B. A., J. Gelin, and Y. Fong: Anticachectin/tumor necrosis factor alpha antibodies attenuate development of cancer cachexia. Cancer Res., 51:415-421 (1991).
34. Simons, J. P., N. K. Aaronson, J. F. Vansteenkiste et al.: Effects of medroxyprogesterone acetate on appetite, weight, and quality of life in advanced-stage non-hormone-sensitive cancer: a placebo-controlled multicenter study. J. Clin. Oncol., 14:1077-1084 (1996).
35. Spitzer, O. W., A. J. Dobson, J. Hall et al.: Measuring the quality of life of cancer patients. A concise QL-Index for use by physicians. J. Chronic Dis., 34:585-597 (1981).
36. Storey, P.: Symptoms control in advanced cancer. Semin. Oncol., 21:748-753 (1994).
37. Strassmann, G., M. Fong, J. S. Kenney et al.: Evidence for the involvement of interleukin-6 in experimental cancer cachexia. J. Clin. Invest., 89:1681-1684 (1992).
38. Suzuki, K., H. Nogimura, H. Wada et al.: Effect of short-term administration of medroxyprogesterone acetate on side reactions of combination chemotherapy with ADR, VDS, and CDDP in primary lung cancer. Gan To Kagaku Ryoho, 18:431-435 (1991).
39. Tchekmedyian, N. S., M. Hickman, J. Siau et al.: Megestrol acetate in cancer anorexia and weight loss. Cancer, 69:1268-1274 (1992).
40. Tchekmedyian, N. S., N. Tait, M. Moody et al.: Appetite stimulation with megestrol acetate in cachectic cancer patients. Semin. Oncol., 13 [Suppl. 4]:37-43 (1986).
41. Tchekmedyian, N. S., N. Tait, M. Moody et al.: High-dose megestrol acetate. A possible treatment for cachexia. JAMA 257:1195-1198 (1987).
42. Tisdale, M. J.: Biology of cachexia. J. Natl. Cancer Inst., 89:1763-1773 (1997).
43. Tisdale, M. J.: Cancer cachexia: metabolic alterations and clinical manifestations. Nutrition, 13:1-7 (1997).
44. Vlassara, H., R. J. Spiegel, D. S. Daval et al.: Reduced plasma lipoprotein lipase activity in patients with malignancy-associated weight loss. Horm. Metab. Res., 18:698-703 (1986).
45. Warren, S.: The immediate causes of death in cancer. Am. J. Med. Sci., 184:610-615 (1932).